2011
Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies,
Zain J, Foss F, Diefenbach C, Petrylak D, Narwal A, Neylon E, Knoblauch P, O'Connor O. Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies,. Blood 2011, 118: 3710. DOI: 10.1182/blood.v118.21.3710.3710.Peer-Reviewed Original ResearchHistone deacetylase inhibitorsTumor shrinkageSolid tumorsDeacetylase inhibitorsIntra-patient dose escalationOngoing phase I trialClass I/II histone deacetylase inhibitorEarly tumor shrinkageGrade 3 diarrheaMedian age 48Frequent adverse eventsNovel histone deacetylase inhibitorPhase I trialHighest dose levelMantle cell lymphomaAnorexia/Dose cohortsEvaluable diseaseQ3w scheduleStable diseaseAdverse eventsDaily doseDose escalationI trialNHL patients
2009
Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma
Zain J, Foss F, Kelly W, DeBono J, Petrylak D, Narwal A, Neylon E, Blumenschein G, Lassen U, O'Connor O. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. Journal Of Clinical Oncology 2009, 27: 8580-8580. DOI: 10.1200/jco.2009.27.15_suppl.8580.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaHodgkin's diseaseDose escalationTumor shrinkageSolid tumorsIntra-patient dose escalationRefractory non-Hodgkin lymphomaPhase IAcceptable organ functionEarly tumor shrinkageMedian age 51Frequent adverse eventsPossible dose escalationMantle cell lymphomaHistone deacetylase inhibitorsEvaluable diseaseLeg DVTPrior regimensQ3w scheduleStable diseaseAdverse eventsDaily doseSafety profileCohort C.Preclinical activity